Policy & Regulation
Merck & Co to assist IO Biotech with clinical trial
15 September 2021 -

IO Biotech, a clinical-stage biopharmaceutical company, announced on Tuesday that it has signed a clinical trial collaboration and supply agreement with United States-based Merck & Co, Inc, through a subsidiary.

The aim of the partnership is to assess IO Biotech's lead candidate, IO102-IO103, along with KEYTRUDA (pembrolizumab), Merck & Co, Inc's anti-PD-1 (programmed death receptor-1) therapy, in patients with cancer.

The product is an investigational cancer vaccine for which IO Biotech will sponsor the clinical trials.

The proposed Phase three trial will be an open label, randomised clinical trial to assess the combination of IO102-IO103 with MSD's anti-PD-1 therapy, KEYTRUDA, compared to KEYTRUDA alone in patients with earlier untreated, unresectable or metastatic melanoma. Biomarker studies will also be carried out.